Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma
出版年份 2017 全文链接
标题
Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-04-05
DOI
10.1038/srep45682
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review
- (2016) Josephine A. Taverna et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma
- (2016) Deepa Jagadeesh et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A randomized, controlled phase III trial ofnab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
- (2015) E. M. Hersh et al. ANNALS OF ONCOLOGY
- Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous?
- (2014) Chunlei Li et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
- (2013) N. Awasthi et al. CARCINOGENESIS
- Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial
- (2013) Julie M. Vose et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin in Hodgkin's lymphoma
- (2012) Barbara Pro et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-Hodgkin lymphoma
- (2012) Kate R Shankland et al. LANCET
- Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
- (2011) R. Griffiths et al. BLOOD
- Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
- (2011) Twan Lammers et al. JOURNAL OF CONTROLLED RELEASE
- Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer
- (2011) Daniel C. Julien et al. mAbs
- Human serum albumin: From bench to bedside
- (2011) Gabriella Fanali et al. MOLECULAR ASPECTS OF MEDICINE
- What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?
- (2011) Joseph G. Jurcic Current Hematologic Malignancy Reports
- The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review
- (2010) Satish K. Garg Diabetes Technology & Therapeutics
- Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
- (2010) David R. Nelson et al. GASTROENTEROLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
- (2008) G. Salles et al. BLOOD
- Application of Nanotechnology in Cancer Therapy and Imaging
- (2008) X. Wang et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
- (2008) Robert Marcus et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
- (2008) Annina Herrmann et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started